DAVITA HEALTHCARE PARTNERS's gross profit margin for the third quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. DAVITA HEALTHCARE PARTNERS has strong liquidity. Currently, the Quick Ratio is 1.72 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has remained unchanged from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY15||Q3 FY14|
|Net Sales ($mil)||3525.67||3251.82|
|Net Income ($mil)||215.87||184.12|
|Balance Sheet||Q3 FY15||Q3 FY14|
|Cash & Equiv. ($mil)||1970.27||1669.16|
|Total Assets ($mil)||18894.83||18101.42|
|Total Debt ($mil)||9196.71||8502.43|
|Profitability||Q3 FY15||Q3 FY14|
|Gross Profit Margin||29.06||28.45|
|Return on Assets||2.56||4.01|
|Return on Equity||9.69||14.62|
|Debt||Q3 FY15||Q3 FY14|
|Share Data||Q3 FY15||Q3 FY14|
|Shares outstanding (mil)||211.01||214.88|
|Div / share||0.0||0.0|
|Book value / share||23.65||23.15|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1519227.0||1124596.0|
BUY. DAVITA HEALTHCARE PARTNERS's P/E ratio indicates a premium compared to an average of 20.25 for the Health Care Providers & Services industry and a premium compared to the S&P 500 average of 20.88. To use another comparison, its price-to-book ratio of 2.73 indicates valuation on par with the S&P 500 average of 2.48 and a discount versus the industry average of 3.57. The current price-to-sales ratio is well below the S&P 500 average, but above the industry average. The valuation analysis reveals that, DAVITA HEALTHCARE PARTNERS seems to be trading at a premium to investment alternatives within the industry.
|DVA 29.03||Peers 20.25||DVA 12.99||Peers 11.80|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
DVA is trading at a significant premium to its peers.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
DVA is trading at a premium to its peers.
|DVA 15.84||Peers 15.80||DVA 2.20||Peers 1.08|
Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.
DVA is trading at a valuation on par with its peers.
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
DVA trades at a significant premium to its peers.
|DVA 2.73||Peers 3.57||DVA -34.13||Peers 35.38|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
DVA is trading at a discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, DVA is expected to significantly trail its peers on the basis of its earnings growth rate.
|DVA 1.00||Peers 0.73||DVA 8.34||Peers 14.99|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
DVA is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
DVA significantly trails its peers on the basis of sales growth
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.